rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2008-535rsp-673Research ArticleСтатьиArticlesТерапия адалимумабом псориатического артритаAdalimumab in treatment of psoriatic arthritisБадокинВ. В.BadokinV. V.-200815082008464№4 (2008)4147Copyright © Бадокин В.В., 20082008Бадокин В.В.Badokin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/673References<div><p>McGonagle D. , Conaghan P. G. , Emery P. Psoriatic arthritis. Arthr. Rheum. , 1999, 42, 1080-1086.</p><p>Olivieri I. , DAngelo S, Scarano E. , Padula A. What is primary lesion in SpA dactylitis? Rheumatology, 2008, 47, 561-562.</p><p>Gelfand J. М., Gladman D. D., Mease P. J. et al. Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol., 2005, 53, 573.</p><p>Gladman D. D. , Rahman P. Psoriatic Arthritis. Chapter 71. In: Kelly's Textbook of Rheumatology. 6th Ed. W. B. Saunders Company:Philadelphia, 2001, 1071-1079.</p><p>Wong K. , Gladman D. D. , Husted J. et al. Mortality studies in psoriatic arthritis. I. Causes and risk death. Arthr. Rhum. , 1997, 40, 1868-1872.</p><p>Ritchlin С. T. The pathogenesis of psoriasis and psoriatic arthritis. New applications for TNF inhibition. Immunex, Philadelphia, 2000, 9-20.</p><p>Mease P. , Antoni С. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005, 64, suppl. II. 78-82.</p><p>Abou-Raja S, Abou-Raja A, Helmii M. Serum levels of some proinflammatory cytokines (TNE-alpha, 1L-6, IL-17, IL-I8) in psoriasis and psoriatic arthritis: reliable disease severity and disease activity biomarkers? Ann. Rheum. Dis. , 2008, 67, suppl. II, 523.</p><p>Насонов E. Л. Применение инфликсимаба при ревматических заболеваниях. М. , 2005, 56 с.</p><p>Ritchlin С. Т. The pathogenesis of psoriatic arthritis. Curr. Opin. Rheumatol. , 2005, 17, 406-4/2.</p><p>Mease P. J. , Gladman D. D. , Ritchlin С. T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthr.Rheum., 2005, 52, 3279-3289.</p><p>Gladman D. D. , Mease P. J. , Ritchlin C. et al. Adalimumab for long-treaiment of psoriatic arthritis. Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trile. Arthr. Rheum. , 2007, 56, 476-488.</p><p>Choy E. H. S. , Gladman D. D. , Mease P. J. et al. PAS 150 is a sensitive indicator of reduced radiographic progression in psoriatic arthritis patients treated with adalimumab (Humira): subanalysis of ADEPT. Ann. Rheum. Dis. , 2008, 67, suppl. II, 524.</p><p>Choy E. H. S. , Gladman D. D. , Mease P. J. et al. Risk Jactors for radiographic progression in patients with psoriatic arthritis: subanalysis ADEPT. 25th Annual General Meeting of the British Society for Rheumatology (BSR); April 22-25, 2008; Liverpool, UK. Abstract 269.</p><p>Abbott Laboratories internal data: PowerPoint file “PsA Clinical Data. "August 20, 2004.</p><p>Mease P. M. , Ritchlin С. M. , Wong R. M. , Gladman D. D. Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2-year results from an openlabel exension study. 66” annual Meeting of the AAD. 2008, San Antonio. Abstract P2606.</p><p>Van der Bosch F. , Manger B. , Goupille P. et al. Clinical remission on joints and skin in patients with psoriatic arthritis treated with adalimumab (Humira) - results of the STEREO trial. Ann. Rheum. Dis. , 2008, 67, suppl. II, 533.</p><p>Genovese М. C. , Mease P. J. , Thompson G. T. et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had Jailed disease modifying antirheumatic drug therapy. J. Rheumatol., 2007,34. 1040-1050.</p><p>Manger В. , Lorenz Н. М. , Splekeler R. et al. Adalimumab (Humira) improves the signs and symptoms ofjoint, skin and nail manifestations of psoriatic arthritis (PsA): results from a German database of PsA patients reseiving adalimumab. Ann. Rheum. Dis. , 2008, 67, suppl. II, 528.</p><p>Burmester G. R. , Hrdicka P. , Georgi J. et al. Adalimumab (Humira) improves the signs and symptoms of psoriatic arthritis (PsA) and is well-toleraded in patients previously with biologies: results from a German database of PsA patients reseiving adalimumab. Ann. Rheum. Dis., 2008, 67, suppl., 533.</p><p>Goedkoop A. Y., Krann М. C. , Teunissen М. В. M. et al. Early effects of tumor necrosis factor-a blokade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rhum. Dis., 2004, 63, 769-773.</p><p>Burmester GR, Mease PJ, Dijkmans В et al. Adalimumab safety profile in global clinical trials and reduction in standardized mortality ratio across multiple indications. Arthr. Rheum., 2007, 56, suppl., 13.</p></div><br /><div><p>McGonagle D. , Conaghan P. G. , Emery P. Psoriatic arthritis. Arthr. Rheum. , 1999, 42, 1080-1086.</p><p>Olivieri I. , DAngelo S, Scarano E. , Padula A. What is primary lesion in SpA dactylitis? Rheumatology, 2008, 47, 561-562.</p><p>Gelfand J. М., Gladman D. D., Mease P. J. et al. Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol., 2005, 53, 573.</p><p>Gladman D. D. , Rahman P. Psoriatic Arthritis. Chapter 71. In: Kelly's Textbook of Rheumatology. 6th Ed. W. B. Saunders Company:Philadelphia, 2001, 1071-1079.</p><p>Wong K. , Gladman D. D. , Husted J. et al. Mortality studies in psoriatic arthritis. I. Causes and risk death. Arthr. Rhum. , 1997, 40, 1868-1872.</p><p>Ritchlin С. T. The pathogenesis of psoriasis and psoriatic arthritis. New applications for TNF inhibition. Immunex, Philadelphia, 2000, 9-20.</p><p>Mease P. , Antoni С. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005, 64, suppl. II. 78-82.</p><p>Abou-Raja S, Abou-Raja A, Helmii M. Serum levels of some proinflammatory cytokines (TNE-alpha, 1L-6, IL-17, IL-I8) in psoriasis and psoriatic arthritis: reliable disease severity and disease activity biomarkers? Ann. Rheum. Dis. , 2008, 67, suppl. II, 523.</p><p>Насонов E. Л. Применение инфликсимаба при ревматических заболеваниях. М. , 2005, 56 с.</p><p>Ritchlin С. Т. The pathogenesis of psoriatic arthritis. Curr. Opin. Rheumatol. , 2005, 17, 406-4/2.</p><p>Mease P. J. , Gladman D. D. , Ritchlin С. T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthr.Rheum., 2005, 52, 3279-3289.</p><p>Gladman D. D. , Mease P. J. , Ritchlin C. et al. Adalimumab for long-treaiment of psoriatic arthritis. Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trile. Arthr. Rheum. , 2007, 56, 476-488.</p><p>Choy E. H. S. , Gladman D. D. , Mease P. J. et al. PAS 150 is a sensitive indicator of reduced radiographic progression in psoriatic arthritis patients treated with adalimumab (Humira): subanalysis of ADEPT. Ann. Rheum. Dis. , 2008, 67, suppl. II, 524.</p><p>Choy E. H. S. , Gladman D. D. , Mease P. J. et al. Risk Jactors for radiographic progression in patients with psoriatic arthritis: subanalysis ADEPT. 25th Annual General Meeting of the British Society for Rheumatology (BSR); April 22-25, 2008; Liverpool, UK. Abstract 269.</p><p>Abbott Laboratories internal data: PowerPoint file “PsA Clinical Data. "August 20, 2004.</p><p>Mease P. M. , Ritchlin С. M. , Wong R. M. , Gladman D. D. Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2-year results from an openlabel exension study. 66” annual Meeting of the AAD. 2008, San Antonio. Abstract P2606.</p><p>Van der Bosch F. , Manger B. , Goupille P. et al. Clinical remission on joints and skin in patients with psoriatic arthritis treated with adalimumab (Humira) - results of the STEREO trial. Ann. Rheum. Dis. , 2008, 67, suppl. II, 533.</p><p>Genovese М. C. , Mease P. J. , Thompson G. T. et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had Jailed disease modifying antirheumatic drug therapy. J. Rheumatol., 2007,34. 1040-1050.</p><p>Manger В. , Lorenz Н. М. , Splekeler R. et al. Adalimumab (Humira) improves the signs and symptoms ofjoint, skin and nail manifestations of psoriatic arthritis (PsA): results from a German database of PsA patients reseiving adalimumab. Ann. Rheum. Dis. , 2008, 67, suppl. II, 528.</p><p>Burmester G. R. , Hrdicka P. , Georgi J. et al. Adalimumab (Humira) improves the signs and symptoms of psoriatic arthritis (PsA) and is well-toleraded in patients previously with biologies: results from a German database of PsA patients reseiving adalimumab. Ann. Rheum. Dis., 2008, 67, suppl., 533.</p><p>Goedkoop A. Y., Krann М. C. , Teunissen М. В. M. et al. Early effects of tumor necrosis factor-a blokade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rhum. Dis., 2004, 63, 769-773.</p><p>Burmester GR, Mease PJ, Dijkmans В et al. Adalimumab safety profile in global clinical trials and reduction in standardized mortality ratio across multiple indications. Arthr. Rheum., 2007, 56, suppl., 13.</p></div><br />
The authors declare that there are no conflicts of interest present.